635 related articles for article (PubMed ID: 26882078)
21. Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis.
Segelmark M; Phillips BD; Hogan SL; Falk RJ; Jennette JC
Clin Diagn Lab Immunol; 2003 Sep; 10(5):769-74. PubMed ID: 12965902
[TBL] [Abstract][Full Text] [Related]
22. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
Slot MC; Tervaert JW; Boomsma MM; Stegeman CA
Arthritis Rheum; 2004 Apr; 51(2):269-73. PubMed ID: 15077271
[TBL] [Abstract][Full Text] [Related]
23. ANCA-associated vasculitis: diagnostic and therapeutic strategy.
Ozaki S
Allergol Int; 2007 Jun; 56(2):87-96. PubMed ID: 17460438
[TBL] [Abstract][Full Text] [Related]
24. Comparison of anti-PR3 capture and anti-PR3 direct ELISA for detection of antineutrophil cytoplasmic antibodies (ANCA) in long-term clinical follow-up of PR3-ANCA-associated vasculitis patients.
Arranz O; Ara J; Rodriguez R; Quintó L; Font J; Mirapeix E; Darnell A
Clin Nephrol; 2001 Oct; 56(4):295-301. PubMed ID: 11680659
[TBL] [Abstract][Full Text] [Related]
25. Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA-Associated Vasculitis: A Retrospective Analysis of 315 Patients From a German Vasculitis Referral Center.
Schirmer JH; Wright MN; Herrmann K; Laudien M; Nölle B; Reinhold-Keller E; Bremer JP; Moosig F; Holle JU
Arthritis Rheumatol; 2016 Dec; 68(12):2953-2963. PubMed ID: 27333332
[TBL] [Abstract][Full Text] [Related]
26. Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse.
Morgan MD; Szeto M; Walsh M; Jayne D; Westman K; Rasmussen N; Hiemstra TF; Flossmann O; Berden A; Höglund P; Harper L;
Arthritis Res Ther; 2017 Jun; 19(1):129. PubMed ID: 28592297
[TBL] [Abstract][Full Text] [Related]
27. Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission.
Gamerith G; Mildner F; Merkel PA; Harris K; Cooney L; Lim N; Spiera R; Seo P; Langford CA; Hoffman GS; St Clair EW; Fervenza FC; Monach P; Ytterberg SR; Geetha D; Amann A; Wolf D; Specks U; Stone JH; Kronbichler A
Ann Rheum Dis; 2023 Feb; 82(2):253-261. PubMed ID: 35973802
[TBL] [Abstract][Full Text] [Related]
28. Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
Murosaki T; Sato T; Akiyama Y; Nagatani K; Minota S
Mod Rheumatol; 2017 Jan; 27(1):95-101. PubMed ID: 27320904
[TBL] [Abstract][Full Text] [Related]
29. Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Kronbichler A; Leierer J; Shin JI; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CGM; St Clair EW; Brunetta P; Fervenza FC; Geetha D; Keogh KA; Monach PA; Ytterberg SR; Mayer G; Specks U; Stone JH;
Arthritis Rheumatol; 2019 Nov; 71(11):1888-1893. PubMed ID: 31216123
[TBL] [Abstract][Full Text] [Related]
30. Changes in proteinase 3 anti-neutrophil cytoplasm autoantibody levels in early systemic granulomatosis with polyangiitis (Wegener's) may reflect treatment rather than disease activity.
Rasmussen N; Salmela A; Ekstrand A; de Groot K; Gregorini G; Cohen Tervaert JW; Gross WL; Wiik A; Jayne DR;
Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S38-44. PubMed ID: 23380137
[TBL] [Abstract][Full Text] [Related]
31. Antibody subtypes and titers predict clinical outcomes in ANCA-associated vasculitis.
Aljuhani M; Makati D; Hoff A; Thompson J; Pellegrino B; Shawwa K; Schmidt R; Kannabhiran D
Rheumatol Int; 2021 May; 41(5):965-972. PubMed ID: 33585954
[TBL] [Abstract][Full Text] [Related]
32. IgA- and SIgA anti-PR3 antibodies in serum versus organ involvement and disease activity in PR3-ANCA-associated vasculitis.
Sandin C; Eriksson P; Segelmark M; Skogh T; Kastbom A
Clin Exp Immunol; 2016 May; 184(2):208-15. PubMed ID: 26762653
[TBL] [Abstract][Full Text] [Related]
33. Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited.
Bensalem A; Mulleman D; Paintaud G; Azzopardi N; Gouilleux-Gruart V; Cornec D; Specks U; Ternant D
Clin Pharmacokinet; 2020 Apr; 59(4):519-530. PubMed ID: 31586310
[TBL] [Abstract][Full Text] [Related]
34. Plasma levels of soluble interleukin 2 receptor, soluble CD30, interleukin 10 and B cell activator of the tumour necrosis factor family during follow-up in vasculitis associated with proteinase 3-antineutrophil cytoplasmic antibodies: associations with disease activity and relapse.
Sanders JS; Huitma MG; Kallenberg CG; Stegeman CA
Ann Rheum Dis; 2006 Nov; 65(11):1484-9. PubMed ID: 16504995
[TBL] [Abstract][Full Text] [Related]
35. Seasonal Influence on the Risk of Relapse at a Rise of Antineutrophil Cytoplasmic Antibodies in Vasculitis Patients with Renal Involvement.
Kemna MJ; Cohen Tervaert JW; Broen K; Timmermans SAMEG; van Paassen P; Damoiseaux JGMC
J Rheumatol; 2017 Apr; 44(4):473-481. PubMed ID: 28202741
[TBL] [Abstract][Full Text] [Related]
36. Increase of Antimyeloperoxidase Antineutrophil Cytoplasmic Antibody (ANCA) in Patients with Renal ANCA-associated Vasculitis: Association with Risk to Relapse.
Yamaguchi M; Ando M; Kato S; Katsuno T; Kato N; Kosugi T; Sato W; Tsuboi N; Yasuda Y; Mizuno M; Ito Y; Matsuo S; Maruyama S
J Rheumatol; 2015 Oct; 42(10):1853-60. PubMed ID: 26373560
[TBL] [Abstract][Full Text] [Related]
37. Rituximab prescription patterns and efficacy in the induction treatment of ANCA-Associated Vasculitis in a Belgian multicenter cohort.
Chasseur P; Blockmans D; von Frenckell C; Nicolas JB; Regniers C; Vandergheynst F
Acta Clin Belg; 2020 Jun; 75(3):163-169. PubMed ID: 30767717
[No Abstract] [Full Text] [Related]
38. Long term azathioprine maintenance therapy in ANCA-associated vasculitis: combined results of long-term follow-up data.
de Joode AAE; Sanders JSF; Puéchal X; Guillevin LP; Hiemstra TF; Flossmann O; Rasmussen N; Westman K; Jayne DR; Stegeman CA
Rheumatology (Oxford); 2017 Nov; 56(11):1894-1901. PubMed ID: 28977502
[TBL] [Abstract][Full Text] [Related]
39. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease.
Casal Moura M; Irazabal MV; Eirin A; Zand L; Sethi S; Borah BJ; Winters JL; Moriarty JP; Cartin-Ceba R; Berti A; Baqir M; Thompson GE; Makol A; Warrington KJ; Thao V; Specks U; Fervenza FC
J Am Soc Nephrol; 2020 Nov; 31(11):2688-2704. PubMed ID: 32826324
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]